Cargando…
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, endocrine-resistant setting. No naturally occurring ESR1 mutations have been rep...
Autores principales: | Martin, Lesley-Ann, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Pancholi, Sunil, Tenev, Tencho, Gellert, Pascal, Buluwela, Laki, Harrod, Alison, Thornhill, Allan, Nikitorowicz-Buniak, Joanna, Bhamra, Amandeep, Turgeon, Marc-Olivier, Poulogiannis, George, Gao, Qiong, Martins, Vera, Hills, Margaret, Garcia-Murillas, Isaac, Fribbens, Charlotte, Patani, Neill, Li, Zheqi, Sikora, Matthew J., Turner, Nicholas, Zwart, Wilbert, Oesterreich, Steffi, Carroll, Jason, Ali, Simak, Dowsett, Mitch |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709387/ https://www.ncbi.nlm.nih.gov/pubmed/29192207 http://dx.doi.org/10.1038/s41467-017-01864-y |
Ejemplares similares
-
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016) -
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
por: Simigdala, Nikiana, et al.
Publicado: (2018) -
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
por: Ribas, Ricardo, et al.
Publicado: (2018) -
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
por: Pancholi, Sunil, et al.
Publicado: (2020) -
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)